Vertex To Launch Phase III Trial Of Telaprevir In Treatment-failure HCV Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech gets U.S. and EU approval to test HCV drug in full range of patients who failed in prior treatment.